Economic Atlas
Companies/Lexaria Bioscience Corp.
Company profile

Lexaria Bioscience Corp.

NASDAQ: LEXX · Healthcare · Biotechnology
Canadian filerHQ Kelowna, BCCIK 0001348362Reports USD
#903 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
44D
Revenue TTM
$368.0k
Rev growth YoY (TTM)
-30.0%
Net income (FY)
-$11.9M
Employees
7
as of 2026-08-22
Market cap
$18.0M
as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$705.9k$705.9k2025
Net income-$11.9M-$11.9M2025
Operating income-$11.9M-$11.9M2025
Total assets$4.2M$4.2M2025
Liabilities$1.6M$1.6M2025
Equity$3.0M$3.0M2025

Revenue trend

FY2019 – FY2025 · USD
FY19
FY19
FY20
FY22
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
IP Licensing99%
B2B1%
By geography

Not disclosed.

The read

What is Lexaria Bioscience Corp.’s revenue?

Lexaria Bioscience Corp. booked $705.9k in FY2025 revenue, growing 52% year over year — faster than most Healthcare companies we track, at a -1686.0% net margin.

Peers · Healthcare
Avivagen Inc.——Relevium Technologies Inc.——Applied Biosciences Corp.——Harvard Apparatus Regenerative Technology Inc.41DAdia Nutrition, Inc.29DUnicycive Therapeutics, Inc.32D
Key facts
CEORichard C. Christopher
SectorHealthcare
IndustryBiotechnology
HeadquartersKelowna, BC
ExchangeNASDAQ: LEXX
Employees7
IPO date2021-01-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.